birb 796 has been researched along with pd 180970 in 1 studies
| Studies (birb 796) | Trials (birb 796) | Recent Studies (post-2010) (birb 796) | Studies (pd 180970) | Trials (pd 180970) | Recent Studies (post-2010) (pd 180970) |
|---|---|---|---|---|---|
| 137 | 5 | 80 | 31 | 0 | 12 |
| Protein | Taxonomy | birb 796 (IC50) | pd 180970 (IC50) |
|---|---|---|---|
| Chain A, Proto-oncogene tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.07 | |
| Chain A, Proto-oncogene tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.07 | |
| Chain A, Proto-oncogene tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.07 | |
| Chain A, Proto-oncogene tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.07 | |
| Chain A, Proto-oncogene tyrosine-protein kinase ABL1 | Mus musculus (house mouse) | 0.07 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.39 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.4782 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.7632 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.664 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.4805 | |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 1.43 | |
| Activin receptor type-1 | Homo sapiens (human) | 1 | |
| Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase | Homo sapiens (human) | 1.4045 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atteridge, CE; Biggs, WH; Carter, TA; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Grotzfeld, RM; Herrgard, S; Insko, DE; Lockhart, DJ; Mehta, SA; Milanov, ZV; Pao, W; Patel, HK; Sawyers, CL; Shah, NP; Treiber, DK; Varmus, H; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
1 other study(ies) available for birb 796 and pd 180970
| Article | Year |
|---|---|
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
Topics: Aminoquinolines; Aniline Compounds; Cell Line; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indoles; Kinetics; Morpholines; Mutation; Naphthalenes; Neoplasms; Oncogene Proteins v-abl; Organic Chemicals; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Sunitinib | 2005 |